Journal article
Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD
Abstract
BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart …
Authors
Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX
Journal
Clinical Journal of the American Society of Nephrology, Vol. 15, No. 12, pp. 1728–1739
Publisher
Wolters Kluwer
Publication Date
December 2020
DOI
10.2215/cjn.08310520
ISSN
1555-9041
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Age FactorsAgedAged, 80 and overBlood GlucoseDatabases, FactualDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleGlomerular Filtration RateHeart FailureHospitalizationHumansKidneyMaleOntarioRenal Insufficiency, ChronicRisk AssessmentRisk FactorsSitagliptin PhosphateTime FactorsTreatment Outcome